TORONTO, ONTARIO — (Marketwire) — 03/26/12 — Attention: Business/Financial Editors
The Medipattern Corporation (“Medipattern” or the “Company”) (TSX VENTURE: MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, continues to grow market share for Visualize:Vascular 3D rendering of the lumen in carotid arteries.
“Medical products need to be validated on three levels to gain market acceptance: 1 – clinical benefit, 2 – reimbursement and 3 – workflow. Visualize:Vascular has been validated on all three points,” commented Jeff Collins, CEO of Medipattern. “First and foremost, medical facilities need to be able to determine the clinical impact of the new diagnostic tool. The white paper(1) and case studies(2, 3) have demonstrated that Visualize:Vascular assists a doctor through its 3D perspective and automated luminal measurements. It has received reimbursement from most major payers. Visualize:Vascular has been shown to be easy to introduce in practice with our installed base. The special cine scan only takes a few minutes and fits well within the standard carotid duplex exam workflow. We have used the product launch phase to validate the product in all three categories. Market share has increased dramatically for Visualize:Vascular. It is encouraging to see that our scanning volumes are steadily increasing week over week. It takes time for all the centers to come up to full volume. We are seeing continued growth in usage volumes as each center goes through the process of installation, training, introduction of the service to referring physicians, and changing order forms to enable using Visualize:Vascular 3D rendering in standard practice,” Collins concluded.
We welcome East River Radiology, with four locations in Manhattan, MD&T of New Jersey: a mobile ultrasound provider with 48 mobile entities, Northshore Primary Care part of the Healthbridge Network with four sites on Long Island, Advanced Radiological Imaging with two locations in New York City and Zwanger-Pesiri Radiology with nine locations on Long Island.
Please visit “our solutions” at to see all of our product updates.
(1) Francis Porreca, MD, FACS, RVPI, Angela Rodriguez-Wong, MD, RVT, RVPI, JP Hughes RVS, RVT, “Three Dimensional Reconstruction of the Vessel Lumen as an Adjunct to the Cerebrovascular Duplex Evaluation” SVU June 2011
(2) Francis Porreca, MD, FACS, RVPI, Angela Rodriguez-Wong, MD, RVT, RVPI, “Case Study: 71 yr old male with bilateral Bruit”
(3) Daniel Gurell, MD, “Case Study: 71 yr old asymptomatic male”
About the Medipattern Corporation:
Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader-s perception. For more information, please visit the Company-s website: .
Medipattern® and B-CAD® are registered trademarks of The Medipattern Corporation. Visualize:Vascular and Cadenza are trademarks of the Medipattern Corporation. SonoCine is a registered trademark of SonoCine, Inc.
Forward-looking statements
This document contains forward-looking statements relating to Medipattern-s performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern-s current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential”, and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company-s corporate filings, (posted at ). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
The Medipattern Corporation
Jeff Collins
CEO
(416) 744-0009 ext. 224
Spinnaker Capital Markets Inc.
Kevin O-Connor
(416) 962-3300 ext. 226
You must be logged in to post a comment Login